BRAIN and NERVE－神経研究の進歩73巻10号

2021年10月発行

特集 中枢神経・末梢神経の悪性リンパ腫

中枢神経系原発悪性リンパ腫—脳神経内科医はどのように向かい合うべきか

著者： 西澤正豊¹

所属機関： ¹新潟医療福祉大学

ページ範囲：P.1067 - P.1074

文献概要

中枢神経系原発悪性リンパ腫に脳神経内科医はいかに向かい合うべきか，前回の本誌特集からの7年間を踏まえて再考する。診療面で最大の進歩は，リキッドバイオプシー試料を用いたゲノム解析手法の進歩にあり，リアルタイムで腫瘍細胞の動態や治療反応性の解析，新規クローンの早期発見を可能としてきた。しかし，脳神経内科医の役割は依然，診断・治療に直接関わることではなく，早期診断して専門治療チームに委ねることにある。

参考文献

1）滑川道人: 中枢神経系における悪性リンパ腫. Brain Nerve 66: 907-916, 2014

2）Morell AA, Shah AH, Cavallo C, Eichberg DG, Sarkiss CA, et al: Diagnosis of primary central nervous system lymphoma: a systematic review of the utility of CSF screening and the role of early brain biopsy. Neurooncol Pract 6: 415-423, 2019

3）Grommes C: Central nervous system lymphomas. Continuum (Minneap Minn) 26: 1476-1494, 2020

4）Pasqualucci L, Dalla-Favera R: Genetics of diffuse large B-cell lymphoma. Blood 131: 2307-2319, 2018

5）Lohr JG, Stojanov P, Lawrence MS, Auclair D, Chapuy B: Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing. Proc Natl Acad Sci U S A 109: 3879-3884, 2012

6）Hohaus S, Giachelia M, Massini G, Mansueto G, Vannata B, et al: Cell-free circulating DNA in Hodgkin's and non-Hodgkin's lymphomas. Ann Oncol 20: 1408-1413, 2009

7）Roschewski M, Dunleavy K, Pittaluga S, Moorhead M, Pepin F, et al: Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker study. Lancet Oncol 16: 541-549, 2015

8）Bohers E, Viailly PJ, Dubois S, Bertrand P, Maingonnat C, et al: Somatic mutations of cell-free circulating DNA detected by next-generation sequencing reflect the genetic changes in both germinal center B-cell-like and activated B-cell-like diffuse large B-cell lymphomas at the time of diagnosis. Haematologica 100: e280-e284, 2015　［doi: 10.3324/haematol.2015.123612］

9）Roschewski M, Staudt LM, Wilson WH: Dynamic monitoring of circulating tumor DNA in non-Hodgkin lymphoma. Blood 127: 3127-3132, 2016

10）Rossi D, Diop F, Spaccarotella E, Monti S, Zanni M, et al: Diffuse large B-cell lymphoma genotyping on the liquid biopsy. Blood 129: 1947-1957, 2017

11）Kurtz DM, Scherer F, Jin MC, Soo J, Craig AFM, et al: Circulating tumor DNA measurements as early outcome predictors in diffuse large B-cell lymphoma. J Clin Oncol 36: 2845-2853, 2018

12）Wu FT, Lu L, Xu W, Li JY: Circulating tumor DNA: clinical roles in diffuse large B cell lymphoma. Ann Hematol 98: 255-269, 2019

13）Schmitz R, Wright GW, Huang DW, Johnson CA, Phelan JD, et al: Genetics and pathogenesis of diffuse large B-cell lymphoma. N Engl J Med 378: 1396-1407, 2018

14）Gonzalez-Aguilar A, Idbaih A, Boisselier B, Habbita N, Rossetto M, et al: Recurrent mutations of MYD88 and TBL1XR1 in primary central nervous system lymphomas. Clin Cancer Res 18: 5203-5211, 2012

15）Deckert M, Montesinos-Rongen M, Brunn A, Siebert R: Systems biology of primary CNS lymphoma: from genetic aberrations to modeling in mice. Acta Neuropathol 127: 175-188, 2014

16）Yamada S, Ishida Y, Matsuno A, Yamazaki K: Primary diffuse large B-cell lymphomas of central nervous system exhibit remarkably high prevalence of oncogenic MYD88 and CD79B mutations. Leuk Lymphoma 56: 2141-2145, 2015

17）Fukumura K, Kawazu M, Kojima S, Ueno T, Sai E, et al: Genomic characterization of primary central nervous system lymphoma. Acta Neuropathol 131: 865-875, 2016

18）NakamuraT, Tateishi K, Niwa T, Matsushita Y, Tamura K, et al: Recurrent mutations of CD79B and MYD88 are the hallmark of primary central nervous system lymphomas. Neuropathol Appl Neurobiol 42: 279-290, 2016

19）Zheng M, Perry AM, Bierman P, Loberiza F Jr, Nasr MR, et al: Frequency of MYD88 and CD79B mutations, and MGMT methylation in primary central nervous system diffuse large B-cell lymphoma. Neuropathol 37: 509-516, 2017

20）Zorofchian S, El-Achi H, Yan Y, Esquenazi Y, Ballester LY: Characterization of genomic alterations in primary central nervous system lymphomas. J Neurooncol 140: 509-517, 2018

21）Zhou Y, Liu W, Xu Z, Zhu H, Xiao D, et al: Analysis of genomic alteration in primary central nervous system lymphoma and the expression of some related genes. Neoplasia 20: 1059-1069, 2018

22）Hiemcke-Jiwa LS, Leguit RJ, Snijders TJ, Jiwa NM, Kuiper JJW, et al: Molecular analysis in liquid biopsies for diagnostics of primary central nervous system lymphoma: review of literature and future opportunities. Crit Rev Oncol Hematol 127: 56-65, 2018

23）King RL, Goodlad JR, Calaminici M, Dotlic S, Montes-Moreno S, et al: Lymphomas arising in immune-privileged sites: insights into biology, diagnosis, and pathogenesis. Virchows Arch 476: 647-665, 2020

24）Rimelen V, Ahle G, Pencreach E, Zinniger N, Debliquis A, et al: Tumor cell-free DNA detection in CSF for primary CNS lymphoma diagnosis. Acta Neuropathol Commun 7: 43, 2019　［doi: 10.1186/s40478-019-0692-8］

25）Watanabe J, Natsumeda M, Okada M, Kobayashi D, Kanemaru Y, et al: High detection rate of MYD88 mutations in cerebrospinal fluid from patients with CNS lymphomas. JCO Precision Oncology 3: 1-12, 2019　［doi: org/10.1200/PO.18.00308］

26）Nayyar N, White MD, Gill CM, Lastrapes M, Bertalan M, et al: MYD88 L265P mutation and CDKN2A loss are early mutational events in primary central nervous system diffuse large B-cell lymphomas. Blood Adv 3: 375-383, 2019

27）Hickmann AK, Frick M, Hadaschik D, Battke F, Bittl M, et al: Molecular tumor analysis and liquid biopsy: a feasibility investigation analyzing circulating tumor DNA in patients with central nervous system lymphomas. BMC Cancer 19: 192, 2019　［doi: 10.1186/s12885-019-5394-x］

28）Lauw MIS, Lucas CG, Ohgami RS, Wen KW: Primary central nervous system lymphomas: a diagnostic overview of key histomorphologic, immunophenotypic, and genetic features. Diagnostics (Basel) 10: 1076, 2020　［doi: 10.3390/diagnostics10121076］

29）Bobillo S, Crespo M, Escudero L, Mayor R, Raheja P, et al: Cell free circulating tumor DNA in cerebrospinal fluid detects and monitors central nervous system involvement of B-cell lymphomas. Haematologica 106: 513-521, 2021

30）Gupta M, Burns E, Georgantas NZ, Thierauf J, Nayyar N, et al: A rapid genotyping panel for detection of primary central nervous system lymphoma. Blood: blood.2020010137, 2021　［doi: 10.1182/blood.2020010137］

31）Ferreri AJM, Calimeri T, Lopedote P, Francaviglia I, Daverio R, et al: MYD88 L265P mutation and interleukin-10 detection in cerebrospinal fluid are highly specific discriminating markers in patients with primary central nervous system lymphoma: results from a prospective study. Br J Haematol 193: 497-505, 2021

32）古谷 剛, 波平智雄, 山崎滋孝, 森 秀生, 服部信孝, 他: 視力低下, 視野生涯を呈した65歳女性. 脳神経55: 87-96, 2003

33）日本脳神経外科学会（監修）, 日本脳腫瘍学会（編）: 2019年度版脳腫瘍診療ガイドライン成人脳腫瘍編, 改訂2版. 2019　https://www.jsn-o.com/guideline3/index1.html（最終閲覧日: 2021年7月15日）

34）Korfel A, Schlegel U: Diagnosis and treatment of primary CNS lymphoma. Nat Rev Neurol 9: 317-327, 2013

35）Lionakis MS, Dunleavy K, Roschewski M, Widemann BC, Butman JA, et al: Inhibition of B cell receptor signaling by ibrutinib in primary CNS lymphoma. Cancer Cell 31: 833-843, 2017

36）Soussain C, Choquet S, Blonski M, Leclercq D, Houillier C, et al: Ibrutinib monotherapy for relapse or refractory primary CNS lymphoma and primary vitreoretinal lymphoma: final analysis of the phase II ‘proof-of-concept’ iLOC study by the Lymphoma study association (LYSA) and the French oculo-cerebral lymphoma (LOC) network. Eur J Cancer 117: 121-130, 2019